MA45112A - Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde - Google Patents

Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde

Info

Publication number
MA45112A
MA45112A MA045112A MA45112A MA45112A MA 45112 A MA45112 A MA 45112A MA 045112 A MA045112 A MA 045112A MA 45112 A MA45112 A MA 45112A MA 45112 A MA45112 A MA 45112A
Authority
MA
Morocco
Prior art keywords
pad4
antibodies
auto
treatment
rheumatoid arthritis
Prior art date
Application number
MA045112A
Other languages
English (en)
Inventor
Carlos Chavez
Alex Godwood
Ethan Paul Grant
Meina Liang
Rachel Patricia Moate
Tomas Mikael Mustelin
Koustubh Ranade
Martin Michael Kari Schwickart
Zhengbin Yao
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MA45112A publication Critical patent/MA45112A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/978Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045112A 2016-05-24 2017-05-23 Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde MA45112A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662340560P 2016-05-24 2016-05-24

Publications (1)

Publication Number Publication Date
MA45112A true MA45112A (fr) 2019-04-10

Family

ID=59009670

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045112A MA45112A (fr) 2016-05-24 2017-05-23 Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde

Country Status (7)

Country Link
US (2) US11613580B2 (fr)
EP (1) EP3464358A1 (fr)
JP (2) JP7217631B2 (fr)
AU (1) AU2017270027B2 (fr)
CA (1) CA3024910A1 (fr)
MA (1) MA45112A (fr)
WO (1) WO2017202879A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45112A (fr) * 2016-05-24 2019-04-10 Medimmune Ltd Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde
WO2020168168A1 (fr) * 2019-02-15 2020-08-20 Inova Diagnostics, Inc. Compositions et méthodes de diagnostic et d'évaluation d'arthrite rhumatoïde
WO2021188409A1 (fr) 2020-03-15 2021-09-23 Kiniksa Pharmaceuticals, Ltd. Traitement du syndrome de relargage des cytokines par des antagonistes du gm-csf
CN111458522B (zh) * 2020-04-20 2024-01-09 杭州英邈生物科技有限公司 一种用于检测血浆白细胞介素6天然抗体的检测试剂、试剂盒及其应用
CN111733151B (zh) * 2020-07-13 2021-11-12 山东新创生物科技有限公司 一种基于padi4作为肿瘤标志物制得的抗原、抗体及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6818406B2 (en) 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
WO2004110244A2 (fr) 2003-05-08 2004-12-23 Vanderbilt University Equation genetique utilisee pour diagnostiquer une polyarthrite rhumatoide
SI1999152T1 (sl) 2006-03-27 2013-02-28 Medimmune Limited Vezni äślen za gm-csf receptor
JP5252339B2 (ja) 2007-12-25 2013-07-31 地方独立行政法人東京都健康長寿医療センター Pad4及び抗pad4抗体の測定方法並びに関節リウマチの検出方法
US9267946B2 (en) * 2009-03-30 2016-02-23 Inserm (Institut National De La Sante Et De La Rec Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
WO2011066372A2 (fr) * 2009-11-25 2011-06-03 The Johns Hopkins University La citrullination de la peptidylarginine désiminase 4 (pad-4) régule sa fonction et son immunogénicité
JP6239517B2 (ja) 2011-10-10 2017-11-29 メディミューン リミテッド 関節リウマチの治療法
US8975033B2 (en) * 2012-11-05 2015-03-10 The Johns Hopkins University Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
WO2015177097A1 (fr) * 2014-05-19 2015-11-26 Medimmune Limited Traitement de la polyarthrite rhumatoïde
MA45112A (fr) * 2016-05-24 2019-04-10 Medimmune Ltd Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde

Also Published As

Publication number Publication date
US20200317793A1 (en) 2020-10-08
AU2017270027B2 (en) 2024-07-11
JP7217631B2 (ja) 2023-02-03
AU2017270027A1 (en) 2018-12-06
US11613580B2 (en) 2023-03-28
JP2019523759A (ja) 2019-08-29
WO2017202879A1 (fr) 2017-11-30
EP3464358A1 (fr) 2019-04-10
US20230303707A1 (en) 2023-09-28
JP2023058524A (ja) 2023-04-25
CA3024910A1 (fr) 2017-11-30

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
EP3661493A4 (fr) Régimes thérapeutiques pour le traitement de l'hémoglobinurie paroxystique nocturne
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3359074A4 (fr) Électroporation pour le traitement de l'obésité ou le diabète
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA45050A (fr) Polynucléotides codant pour la lipoprotéine lipase destinés au traitement de l'hyperlipidémie
EP3645040A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers
MA45112A (fr) Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde
EP3645039A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
EP3463341A4 (fr) Immunomodulateurs à base d'aminocylindazole pour le traitement de maladies auto-immunes
EP3630102A4 (fr) Formulations pour le traitement d'un trouble de stress post-traumatique
MA56412A (fr) Thérapie par l'arn messager pour le traitement des maladies articulaires
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3434291A4 (fr) Composition pour le traitement d'un disque intervertébral
MA45492A (fr) Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3384035A4 (fr) Dosages pour la détection d'anticorps neutralisants de vaa
EP3393468A4 (fr) Méthodes pour le traitement d'une maladie immunodéficiente
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3507703A4 (fr) Plate-forme distribuée pour l'exécution robuste d'applications domestiques intelligentes